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Summary A human bladder carcinoma cell line was irradiated at high and low dose rates and exposed to
camptothecin and VP16, inhibitors of topoisomerase I and topoisomerase II respectively. Although camp-
tothecin substantially modifed the cytotoxic effects of high dose rate irradiation, abolished low dose rate
sparing and inhibited the repair of sublethal and potentially lethal damage, VP16 had no effect on the survival
curves even at highly cytotoxic doses. Thus, it is argued that there is a role for topoisomerase I but not
topoisomerase II in the repair of DNA damage induced by ionising radiation.
DNA topoisomerases are proposed as regulators of the
superhelical configuration of cellular DNA. By passing DNA
strands through one another (single-stranded in the case of
topoisomerase I, double-stranded in that of topoisomerase II)
these enzymes are able to relax supercoils in the chromatin
(Wang, 1985). Topoisomerase II has been shown to be
located at the base of chromatin loops (Wang, 1985) and to
be regulated in its expression through the cell cycle (Heck et
al., 1988). It has been proposed as playing an important role
in the control of changes in structure of the DNA through-
out the cycle; condensation and separation of chromatids
during mitosis (Earnshaw et al., 1985; Holm et al., 1985;
Uemera et al., 1987), decondensation during GI, replication
during S (Mattern & Painter, 1979; Mattern & Scudiero,
1981; Nelson et al., 1986) possibly involving the separation of
recombinant structures, subsequent recondensation during G2
and also the unwinding of specific regions for gene expression
(Mattern & Scudiero, 1981; Nishio & Uyeki, 1982; Rowe et
al., 1986). Topoisomerase I has been implicated in replication
(Yanagida & Wang, 1987) and transcription (Garg et al.,
1987). The hypothesis has also been advanced that
topoisomerase activity might have a role to play in the repair
of DNA damage in that localised unwinding of the
chromatin may be necessary to render lesions readily access-
ible to bulky repair complexes. Recently Downes & Johnson
(1988) have speculated that the association of topoisomerase
I with transcriptionally active areas of the DNA (Fleis-
chmann et al., 1984) may be indicative of a role for this
enzyme in the preferential excision of lesions observed in
such areas (Bohr et al., 1985).
Numerous inhibitors of topoisomerase activity have been
identified, affecting specifically both topoisomerase I (for
example, camptothecin: Mattern et al., 1987; Hsiang et al.,
1985, Eng et al., 1988) and topoisomerase II (for example
VP16: Chen et al., 1984). In this study, camptothecin and
VP16 were employed in an attempt to modify the radiation
sensitivity of a human tumour cell line to demonstrate a
possible role for topoisomerases in the repair of ionising
radiation-induced DNA damage. A previous study demon-
strated a sensitisation of cells by novobiocin (Kelland &
Steel, 1988), reportedly an inhibitor of topoisomerase II,
although Warters et al. (1989) found no sensitisation.
Novobiocin has been shown to be a general inhibitor of
oxidative metabolism (Downes et al., 1985) so that these
experiments have not established unequivocally the involve-
ment of topoisomerase in the repair process (Downes &
Johnson, 1988). A combination of the two agents was also
used following a report that topoisomerases may be able to
substitute for one another (Yanagida & Wang, 1987).
Materials and methods
The cell line chosen was RT112, a radioresistant bladder
carcinoma line with a high degree of dose-rate sparing.
Irradiation was carried out both at high (160 cGy min-') and
low (3 cGymin-') dose rates.
Cell culture
The cell line, RT112, is an aneuploid line established from a
bladder carcinoma and originally maintained as a xenograft.
Cells were maintained as monolayers in Ham's F12 sup-
plemented with 10% fetal calf serum under an atmosphere of
5% 02, 5% C02, 90% N2. The generation time was approx-
imately 26 h. RT112 is one of the most resistant of tumour
lines to ionising radiation (Steel & Peacock, 1989) and it is
also one of the most resistant to the cytotoxic effects of
topoisomerase inhibitors; it does not, however, display
unusual levels of topoisomerase activity (unpublished obser-
vations). For colony assays the cells were grown to
confluence and maintained in that state for a week so that all
the cells would be in a Go state at the time of treatment.
Irradiation and colonyformation
Single-cell suspensions were plated out at appropriate den-
sities in triplicate culture flasks containing 5 ml medium,
gassed with 5% 02, 5% C02, 90% N2 and held at 37°C for
30 min before irradiation with 'Co gamma rays at dose rates
of 160 and 3 cGy min-'. After irradiation, the flasks were
incubated for 12 days at 37°C, then stained with a solution of
0.5% methylene blue in 50% methanol. Colonies containing
50, or more, cells were counted by eye.
Chemicals
Camptothecin was obtained from Sigma (Poole, UK) and
VP16 (etoposide) from Bristol-Myers (Slough, UK). In col-
ony assay studies they were added at the time of plating out
and removed 5 h later.
Topoisomerase I assay
The effect of camptothecin upon the activity of
topoisomerase I in cellular extracts was carried out essentially
according to the protocol of Johnstone & McNerney (1985).
Briefly, combined cytosolic and nuclear extracts were
prepared and incubated for 30 min at 37°C with supercoiled
pBR322 plasmid DNA either in the absence, or presence, of
varying concentrations of camptothecin. The reaction was
stopped by the addition of stop solution containing SDS, the
plasmid samples were then run on a 1% agarose gel over-
night and the activities of the camptothecin-treated extracts
in relaxing the plasmid were estimated relative to that seen in
untreated extract.
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Results 1
Camptothecin
The effects of camptothecin on radiosensitivity at high and
low dose rates are shown in Figure 1. The concentration used
was 0.87 gmlg ' which induces less than 15% lethality in
unirradiated cells. Although camptothecin appeared to sen-
sitise cells to radiation at high dose rate to some degree,
showing a dose enhancement ratio (DER: the ratio of the
dose required to reduce survival to 10% in the absence of
drug to that in its presence) of 1.10, it had an even greater
effect at low dose rate (DER value of 1.32) such that the low
dose rate sparing was completely abolished.
VPJ6
Figure 2 shows the effects of a 50#g ml-' concentration of
VP16 on the radiosensitivity of RT112. Although this con-
centration was sufficient to kill 70% of unirradiated cells, it
had no effects upon the shape of the survival curves, nor did
a range of lower concentrations, from 5 to 25 igml-' (data
not shown).
Camptothecin plus VP16
Figure 3 shows the effects of combining the exposures to the
two drugs on the radiosensitivity of RT112. No difference
was seen between the effects of exposure to camptothecin
alone and a combined exposure (DER values of 1.09 and
1.33 for high and low dose rate irradiations respectively).
The effect ofcamptothecin on repair ofSLD
Figure 4 shows the results of split-dose experiments in which
two doses of Gy were separated by increasing intervals of
time from 1 to 4 h. Camptothecin, where appropriate, was
present for 30 min before the first irradiation and for the
subsequent 5 h. The results are expressed in terms of the
recovery ratio, that is, the ratio of the surviving fraction
measured at each time interval to that seen with no dose
separation. In the absence of camptothecin the recovery ratio
was 2.60 ± 0.37 and repair was complete within 3 h. How-
ever, when camptothecin was present between the doses there
was a reduction in the recovery ratio to 1.78 ± 0.24.
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Figure 1 Survival curves determined at high (U, 0:
160 cGy min-') and low (0, 0: 3 cGy min') dose rate either
alone (closed symbols, dashed lines) or in the presence of
0.87 lgml-' camptothecin (open symbols). Each point represents
the mean of four experiments.
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Figure 2 Survival curves determined at high (O, 0) and low
(0, 0) dose rate either alone (closed symbols) or in the presence
of 50 Agml-' VP16 (open symbols). Each point represents the
mean of four experiments.
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Figure 3 Survival curves determined at high (0, C) and low
(-, O) dose rate either alone (closed symbols, dashed lines) or in
the presence of both camptothecin and VP16 (open symbols).
Each point represents the mean of three experiments.
The effiect ofcamptothecin on the repair ofPLD
The results of delayed plating experiments, to determine the
effects of camptothecin on the repair of PLD, are shown in
Figure S. Fully confluent cultures were irradiated with 8 Gy
and held for various intervals of time before the cells were
harvested and plated out for colony formation. Camp-
tothecin was added 30 min before irradiaton and removed at
the time of harvesting. Again results are expressed in terms
of a recovery ratio relevant to the level of survival observed
following immediate replating. In the absence of camp-
tothecin the recovery ratio rose to 2.41 ± 0.31 within 6 h; in
the presence of camptothecin little recovery was seen within
the 8 h period examined.
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Figure 4 Repair of sublethal damage as measured by split dose
recovery. Cells were irradiated with two doses of 4 Gy separated
by increasing intervals of time in the absence (O) or presence
(0) of 0.87 pg ml-' camptothecin. Each point represents the
mean ± S.E. of three experiments.
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Figure 5 Repair of potentially lethal damage following 8 Gy in
the absence (-) or presence (0) of 0.87 ltg ml-' camptothecin;
cells were held in a confluent state for increaseing times after
irradiation. Each point represents the mean S.E. of three
experiments.
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Figure 6 Inhibition by camptothecin of the DNA unwinding
activity of cellular extract. Each point represents the mean ± S.E.
of three experiments.
The effect ofcamptothecin on the activity of topoisomerase I
Cellular extracts were prepared from RTl 12 and used to
unwind supercoiled plasmid DNA in the presence of various
concentrations of camptothecin. The drug inhibited the
unwinding activity of the extracts such that 0.87 fig ml', the
concentration used for the survival experiments, reduced
activity to 30% of that seen in the untreated controls (Figure
6).
Discussion
Numerous studies have been published reporting on the
effects of inhibitors of topoisomerase on the repair of lesions
induced by ultraviolet radiation. However, many of these
have used novobiocin which has been shown to exert its
effect by a general inhibition of oxdiative metabolism
(Downes et al., 1985); a role for topoisomerase was, thus, not
conclusively demonstrated by these experiments. Studies
using specific inhibitors of topoisomerases, such as VP16, are
fewer but again have concentrated on ultraviolet radiation.
These have tended to show little or no effect of VP16, or
mAMSA, on DNA repair processes in intact human cells
(Wilkins, 1983; Downes et al., 1987; Snyder, 1987). Similarly
the murine L cell mutant tsAlS9 which has a temperature
sensitive topoisomerase II (Colwill & Sheinin, 1983) has been
shown to be repair-competent at the non-permissive
temperature (Cleaver, 1972).
Little, or no, information has been published on the effects
of inhibitors of topoisomerases on sensitivity to ionising
radiation. Here we report that camptothecin, but not VP16,
significantly affected cell survival at non-toxic doses following
both high and low dose-rate irradiation. If, and only if, these
inhibitors are indeed specific for the respective enzymes, then
this would tend to argue that topoisomerase I, but not
topoisomerase II, is involved in the cellular recovery from
ionising radiation-induced damage. No evidence was found
that the two topoisomerases could substitute for one another
in the recovery process; a combiantion of the two inhibitors
had exactly the same effect as camptothecin alone, no addi-
tional kill being generated by the presence of VP16. Again
assuming the specificity of camptothecin, it can be
hypothesised that the enzymic activity of topoisomerase I is
required in the resolution of some form(s) of DNA damage
induced by ionising radiation and that trapping of the
topoismerase I molecules on DNA by complex formation
with camptothecin leads to the failure of repair and eventual
fixation of that damage. The molecular basis for this effect
remains obscure but the damage appears to be that which is
resolved during the processes of low dose-rate sparing,
sublethal damage repair and potentially lethal damage repair.
That the concentration of camptothecin required to prevent
cellular recovery lay in the range over which topoisomerase I
activity is inhibited lends supporting evidence to the
hypothesis that the drug is affecting survival through a
topoisomerase-mediated mechanism.
The lack of involvement of topoisomerase II in the repair
of damage induced by ionising radiation has also been pro-
posed by Warters et al. (1989) who found that inhibiton of
topoisomerase II (albeit using novobiocin) had no effect on
the rate of double-strand break rejoining, or on cell killing
following radiation. Similarly Collins & Johnson (1979)
found no inhibition of repair of ionising radiation-induced
DNA lesions by concentrations of novobiocin that
significantly disrupted the repair of u.v.-irradiated DNA. Our
results provide further evidence for this viewpoint and
indicate that inhibitors of topoisomerase II are unlikely to
prove of value as modifiers of the initial slope of the acute
cell survival curve. It is apparent that the clinical radiore-
sponsiveness of human tumours correlates with the steepness
of this initial slope (Fertil & Malaise, 1981; Deacon et al.,
1984) so that the modification of this slope by inhibitors of
DNA repair in vitro could point to a possible therapeutic
gain in vivo. Although VP16 does not appear to be a can-
didate for use as a radiosensitiser, camptothecin looks moreINHIBITION OF RECOVERY BY TOPOISOMERASE INHIBITORS 367
promising in that it reduced survival at a dose of 2 Gy from
0.8 to 0.64.
Indeed, camptothecin has been shown to have anti-
tumorigenic activity (Gallo et al., 1971; Wani et al., 1986)
and, in a selection of derivative compounds, the level of this
activity has been shown to correlate with the degree of
inhibition of topoismerase I (Jaxel et al., 1989). It seems
possible that a combination of high concentrations of camp-
tothecin and gamma irradiation could prove to be par-
ticularly effective in generating an antitumorigenic effect in
that we have shown a component ofcell killing that is due to
an interaction between the two agents. We are currently
investigating this interaction and extending our studies to
normal cell lines to determine whether there may be any
therapeutic advantage in using this combination of
antitumorigenic agents.
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